Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: Final analysis of survival and toxicity in the groupe d'etude des lymphames folliculaires 86 trial

Journal of Clinical Oncology

Volumn 16, Issue 7, 1998, Pages 2332-2338

  Solal Céligny, Philippe ^a   Lepage, Eric ^b   Brousse, Nicole ^b   Tendler, Craig L ^b   Brice, Pauline ^b   Haïoun, Corinne ^b   Gabarre, Jean ^b   Pignon, Bernard ^b   Tertian, Gérard ^b   Bouabdallah, Réda ^b   Rossi, Jean François ^b   Doyen, Chantai ^b   Coiffier, Bertrand ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; PREDNISONE; TENIPOSIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; ASTHENIA; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PATIENT CODING; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

EID: 0345164436     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.7.2332     Document Type: Article

References (25)

1. Holford TR, Zheng T, Mayne ST, et al: Time trends of non- Hodgkin's lymphoma: Are they real? What do they mean? Cancer Res 52:54745-54765, 1992 (suppl 2)
2. Horning SJ: Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20:75-88, 1993 (suppl 5)
3. Gutterman JU: Cytokine therapeutics: Lessons from interferon α. Proc Natl Acad Sci U S A 91:1198-1205, 1994
4. Wadler S, Schwartz EL: Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies. Cancer Res 50:3473-3486, 1990
5. Kreuser ED, Wadler S, Thiel E: Interactions between cytokines and cytotoxic drugs. Putative molecular mechanisms in experimental hematology and oncology. Semin Oncol 19:1-7, 1992 (suppl 4)
6. Solal-Céligny P, Lepage E, Brousse N, et al: Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med 329:1608-1614, 1993
7. Cole BF, Solal-Céligny P, Gelber RD, et al: Quality-of-life adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: An aid to clinical decision making. J Clin Oncol 16:2339-2344, 1998
8. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
9. Brice P, Bastion Y, Lepage E, et al: Comparison in low tumor burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon-alfa: A randomized study from the Groupe d'Etude des Lymphomes Folliculaires. J Clin Oncol 15:1110-1117, 1997
10. Hagenbeek A, Carde P, Meerwaldt JH, et al: Maintenance of remission with human recombinant interferon alpha-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. J Clin Oncol 16:41-47, 1998
11. Avilès A, Duque G, Talavera A, et al: Interferon alfa 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival. Leuk Lymph 20:495-499, 1996
12. Hermann R, Unterhalt M, Koch P, et al: Long-term interferon alfa maintenance prolongs remission duration in advanced low-grade lymphomas and is related to the efficacy of initial cytoreductive chemotherapy. Blood 88:453A, 1996 (abstr, suppl 1)
13. Peterson BA, Petroni G, Oken MM, et al: Cyclophosphamide vs cyclophosphamide plus interferon alfa-2b in follicular lymphomas: An intergroup phase III trial. Proc Am Soc Clin Oncol 16:21, 1997 (abstr 48)
14. Smalley RV, Andersen JW, Hawkins MJ, et al: Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med 327:1336-1341, 1992
15. Andersen JW, Smalley RV: Interferon alfa plus chemotherapy for non-Hodgkin's lymphoma: Five-year follow-up. N Engl J Med 329:1821-1822, 1993
16. Rohatiner A, Crowther D, Radford J, et al: The role of interferon in follicular lymphoma. Proc Am Soc Clin Oncol 15:418, 1996 (abstr 1285)
17. Gallagher CJ, Gregory WM, Jones AE, et al: Follicular lymphoma: Prognostic factors for response and survival. J Clin Oncol 4-1470-1480, 1986
18. Romaguera JE, Mclaughlin P, North L, et al: Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: A risk model. J Clin Oncol 9:762-769, 1991
19. Coiffier B, Bastion Y, Berger F, et al: Prognostic factors in follicular lymphomas. Semin Oncol 20:89-96, 1993 (suppl 5)
20. Leonard RCF, Hayward RL, Prescott RJ, et al: The identification of discrete prognostic groups in low-grade non-Hodgkin's lymphoma. The Scotland and Newcastle Lymphoma Group Therapy Working Party. Ann Oncol 2:655-662, 1991
21. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993
22. Bastion Y, Coiffier B: Is the International Prognostic Index for aggressive lymphoma useful for follicular lymphoma patients? J Clin Oncol 12:1340-1342, 1994
23. Lopez-Guillermo A, Montserrat E, Bosch F, et al: Applicability of the International Prognostic Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 12:1343-1348, 1994
24. Hermans J, Krol ADG, Van Groningen K, et al: The International Prognosis Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 86:1460-1463, 1995
25. Avilès A: The International Index is not useful in the classification of low-grade lymphoma. J Clin Oncol 12:2766-2770, 1994